TriLink BioTechnologies and Lonza Form Non-Exclusive Licensing Agreement for Efficient mRNA Capping Technologies

TriLink BioTechnologies, a Maravai LifeSciences company and global provider of life science reagents and services, has entered into a non-exclusive License and Supply Agreement with Lonza, a global development and manufacturing partner for the pharma, biotech, and nutrition industries. The agreement aims to increase access to CleanCap mRNA capping technologies in response to the growing demand for mRNA.

Under the terms of the agreement, TriLink will supply Lonza with its patented CleanCap M6, CleanCap AG 3’OMe, CleanCap AG, and CleanCap AU cap analogs for use in Lonza’s global mRNA development and manufacturing services. These solutions will be used from pre-clinical to Phase III programs.

The CleanCap technology offered by TriLink is known for its high efficiency capping process, with over 95% capping efficiency. This simplifies the mRNA production process when compared to traditional capping methods. Drew Burch, President of Nucleic Acid Production at TriLink expressed excitement about providing their innovative capping solutions to Lonza and its clients. He highlighted how CleanCap technology has been instrumental in speeding up programs from discovery to clinical trials by enhancing mRNA function, streamlining manufacturing processes, and increasing capped material yield.

TriLink’s CleanCap capping technology has been utilized in a majority of approved mRNA and saRNA vaccines since it was introduced in 2017. In May 2023, TriLink introduced its most robust CleanCap analog to date, CleanCap M6 which has shown to increase mRNA expression by more than 30% compared to enzymatic capping methods.

Overall, this partnership between TriLink BioTechnologies and Lonza will bring together two leading companies in the life sciences industry to provide innovative solutions that meet the growing demand for mRNA technology.

In recent years there has been an increased focus on developing new therapies based on messenger RNA (mRNA), which are responsible for coding proteins in our cells. However one of the challenges associated with using mRNA as a therapeutic agent is achieving efficient delivery into target cells while maintaining stability within those cells.

To overcome this challenge many companies have developed various techniques such as chemical modifications or physical encapsulation of mRNAs that enhance their stability within target cells after delivery.

One such technique is provided by TriLink BioTechnologies through their patented CleanCap technology that offers high efficiency capping processes with over 95% capping efficiency compared to traditional methods.

With this partnership between TriLink BioTechnologies and Lonza we can expect further advancements in delivering stable and efficient messenger RNAs as therapeutic agents in various fields like Pharma, Biotech